» Articles » PMID: 34650571

Advances in Adoptive Cell Therapy Using Induced Pluripotent Stem Cell-Derived T Cells

Overview
Journal Front Immunol
Date 2021 Oct 15
PMID 34650571
Citations 10
Authors
Affiliations
Soon will be listed here.
Abstract

Adoptive cell therapy (ACT) using chimeric antigen receptor (CAR) T cells holds impressive clinical outcomes especially in patients who are refractory to other kinds of therapy. However, many challenges hinder its clinical applications. For example, patients who undergo chemotherapy usually have an insufficient number of autologous T cells due to lymphopenia. Long-term expansion can result in T cell exhaustion, which reduces the effector function. There is also a batch-to-batch variation during the manufacturing process, making it difficult to standardize and validate the cell products. In addition, the process is labor-intensive and costly. Generation of universal off-the-shelf CAR T cells, which can be broadly given to any patient, prepared in advance and ready to use, would be ideal and more cost-effective. Human induced pluripotent stem cells (iPSCs) provide a renewable source of cells that can be genetically engineered and differentiated into immune cells with enhanced anti-tumor cytotoxicity. This review describes basic knowledge of T cell biology, applications in ACT, the use of iPSCs as a new source of T cells and current differentiation strategies used to generate T cells as well as recent advances in genome engineering to produce next-generation off-the-shelf T cells with improved effector functions. We also discuss challenges in the field and future perspectives toward the final universal off-the-shelf immunotherapeutic products.

Citing Articles

Targeting cancer with precision: strategical insights into TCR-engineered T cell therapies.

Lin P, Lin Y, Mai Z, Zheng Y, Zheng J, Zhou Z Theranostics. 2025; 15(1):300-323.

PMID: 39744228 PMC: 11667231. DOI: 10.7150/thno.104594.


Combining the induced pluripotent stem cell (iPSC) technology with chimeric antigen receptor (CAR)-based immunotherapy: recent advances, challenges, and future prospects.

Alidadi M, Barzgar H, Zaman M, Paevskaya O, Metanat Y, Khodabandehloo E Front Cell Dev Biol. 2024; 12:1491282.

PMID: 39624236 PMC: 11609223. DOI: 10.3389/fcell.2024.1491282.


Recent updates on allogeneic CAR-T cells in hematological malignancies.

Mansoori S, Noei A, Maali A, Seyed-Motahari S, Sharifzadeh Z Cancer Cell Int. 2024; 24(1):304.

PMID: 39227937 PMC: 11370086. DOI: 10.1186/s12935-024-03479-y.


Regulation of CAR transgene expression to design semiautonomous CAR-T.

Glowacki P, Treda C, Rieske P Mol Ther Oncol. 2024; 32(3):200833.

PMID: 39184876 PMC: 11344471. DOI: 10.1016/j.omton.2024.200833.


Immune cells and RBCs derived from human induced pluripotent stem cells: method, progress, prospective challenges.

Jiang J, Ren R, Cheng Y, Li X, Zhang G Front Cell Dev Biol. 2024; 11:1327466.

PMID: 38250324 PMC: 10796611. DOI: 10.3389/fcell.2023.1327466.


References
1.
DiNofia A, Grupp S . Will allogeneic CAR T cells for CD19 malignancies take autologous CAR T cells 'off the shelf'?. Nat Rev Clin Oncol. 2021; 18(4):195-196. DOI: 10.1038/s41571-021-00485-1. View

2.
Benjamin R, Graham C, Yallop D, Jozwik A, Mirci-Danicar O, Lucchini G . Genome-edited, donor-derived allogeneic anti-CD19 chimeric antigen receptor T cells in paediatric and adult B-cell acute lymphoblastic leukaemia: results of two phase 1 studies. Lancet. 2020; 396(10266):1885-1894. PMC: 11773457. DOI: 10.1016/S0140-6736(20)32334-5. View

3.
Leen A, Bollard C, Mendizabal A, Shpall E, Szabolcs P, Antin J . Multicenter study of banked third-party virus-specific T cells to treat severe viral infections after hematopoietic stem cell transplantation. Blood. 2013; 121(26):5113-23. PMC: 3695359. DOI: 10.1182/blood-2013-02-486324. View

4.
Maeda T, Nagano S, Ichise H, Kataoka K, Yamada D, Ogawa S . Regeneration of CD8αβ T Cells from T-cell-Derived iPSC Imparts Potent Tumor Antigen-Specific Cytotoxicity. Cancer Res. 2016; 76(23):6839-6850. DOI: 10.1158/0008-5472.CAN-16-1149. View

5.
Honda T, Ando M, Ando J, Ishii M, Sakiyama Y, Ohara K . Sustainable Tumor-Suppressive Effect of iPSC-Derived Rejuvenated T Cells Targeting Cervical Cancers. Mol Ther. 2020; 28(11):2394-2405. PMC: 7646217. DOI: 10.1016/j.ymthe.2020.07.004. View